A Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Epithelial Ovarian Cancer
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha Antibody Drug Conjugate, in Combination With Bevacizumab in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers)
Sponsor: Sutro Biopharma, Inc.
Terminated
Terminated Early
Listed as NCT05200364, this PHASE1 trial focuses on Fallopian Tube Cancer and Ovarian Cancer and remains terminated or withdrawn. Sponsored by Sutro Biopharma, Inc., it has been updated 8 times since 2022, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
8 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE1
-
Sep 2025 — Oct 2025 [monthly]
Terminated PHASE1
Status: Recruiting → Terminated
-
Dec 2024 — Sep 2025 [monthly]
Recruiting PHASE1
Status: Active Not Recruiting → Recruiting
-
Sep 2024 — Dec 2024 [monthly]
Active Not Recruiting PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting PHASE1
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Feb 2022 — Apr 2022 [monthly]
Recruiting PHASE1
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Sutro Biopharma, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .